Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of GSK's herpes zoster vaccine co-administered with Prevnar13 in adults 50+ years; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• GSK1437173A (GSK1437173A)
• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2021-03-18